NCT03277456View on ClinicalTrials.gov

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

November 2, 2017

Study Completion Date

November 2, 2017

Conditions
Human Volunteers
Interventions
BIOLOGICAL

MVA-NP+M1

Intramuscular injection of novel vaccine

Trial Locations (1)

OX3 7LJ

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford

Sponsors
All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

Barinthus Biotherapeutics

INDUSTRY

NCT03277456 - A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1 | Biotech Hunter | Biotech Hunter